In this episode, Chris Parker, MD, and Bertrand Tombal, MD, PhD, discuss the clinical implications of the latest data on radiopharmaceuticals in the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). Topics include:

• Data from the PEACE-3 trial on the effect of bone-protective agents on fracture risk with enzalutamide plus radium-223
• Efficacy and toxicity of PSMA lutetium plus standard of care in the VISION trial
• Ongoing trials evaluating radionuclides in combination with other agents in metastatic CRPC

Presenters:

Chris Parker, MD
Professor of Prostate Oncology
Institute of Cancer Research
Clinical Oncologist
Department of Uro-oncology
Royal Marsden Hospital
Sutton, Surrey, United Kingdom

Bertrand Tombal, MD, PhD
Professor of Urology
Institut de Recherche Clinique (IRC)
Cliniques universitaires Saint-Luc
Chairman
Department of Surgery
Cliniques universitaires Saint-Luc
Brussels, Belgium

Link to full program, including downloadable slides: 
https://bit.ly/36IEnNE

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.